$1.01 Billion is the total value of BB BIOTECH AG's 20 reported holdings in Q1 2012. The portfolio turnover from Q4 2011 to Q1 2012 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2012 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2012-05-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Annexon, Inc. | April 22, 2024 | 4,682,290 | 5.2% |
| AGIOS PHARMACEUTICALS, INC. | February 13, 2024 | 4,000,000 | 7.2% |
| Black Diamond Therapeutics, Inc. | February 13, 2024 | 8,517,839 | 16.5% |
| ESSA Pharma Inc. | February 13, 2024 | 7,879,583 | 17.9% |
| Generation Bio Co. | February 13, 2024 | 3,608,280 | 5.5% |
| IONIS PHARMACEUTICALS INC | February 13, 2024 | 8,590,000 | 6.0% |
| MACROGENICS INC | February 13, 2024 | 9,929,963 | 16.0% |
| Molecular Templates, Inc. | February 13, 2024 | 1 | 19.2% |
| Revolution Medicines, Inc. | February 13, 2024 | 5,046,700 | 3.1% |
| Sage Therapeutics, Inc. | February 13, 2024 | 3,505,000 | 5.8% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-08-14 |
| 13F-NT | 2024-05-15 |
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.